Clinically relevant measures of fit? A note of caution.
暂无分享,去创建一个
[1] Nancy R Cook,et al. Comments on ‘Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers’ by M. J. Pencina, R. B. D'Agostino, Sr. and E. W. Steyerberg , 2012, Statistics in medicine.
[2] David A. Hinds,et al. Assessment of Clinical Validity of a Breast Cancer Risk Model Combining Genetic and Clinical Information , 2010, Journal of the National Cancer Institute.
[3] J. Cuzick,et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Pencina,et al. Interpreting incremental value of markers added to risk prediction models. , 2012, American journal of epidemiology.
[5] N. Cook,et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. , 2007, JAMA.
[6] J. Cuzick,et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] N. Cook. Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.
[8] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[9] J. Shaughnessy,et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. , 2011, Blood.
[10] Ewout W Steyerberg,et al. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.
[11] K. Thursky,et al. Use of risk stratification to guide ambulatory management of neutropenic fever , 2011, Internal medicine journal.
[12] Khan Aa,et al. Risk stratification after acute myocardial infarction. , 2001, JPMA. The Journal of the Pakistan Medical Association.
[13] Nancy R Cook,et al. The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women , 2006, Annals of Internal Medicine.
[14] Holly Janes,et al. Commentary: Reporting standards are needed for evaluations of risk reclassification. , 2011, International journal of epidemiology.
[15] Paul M. Ridker,et al. Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women , 2007 .
[16] J. Kassirer,et al. Therapeutic decision making: a cost-benefit analysis. , 1975, The New England journal of medicine.
[17] M. Pencina,et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.
[18] N. Unwin,et al. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .
[19] C. Begg,et al. One statistical test is sufficient for assessing new predictive markers , 2011, BMC Medical Research Methodology.
[20] Nancy R Cook,et al. Performance of reclassification statistics in comparing risk prediction models , 2011, Biometrical journal. Biometrische Zeitschrift.